COMPASS Pathways (CMPS) Q3 2024 earnings summary

Executive summary

• Strategic reorganization to focus exclusively on COMP360, including a 30% workforce reduction and discontinuation of non-COMP360 preclinical efforts.

• Top-line COMP005 phase 3 data now expected in Q2 2025; COMP006 data delayed to H2 2026 due to recruitment and regulatory considerations.

• Cash position of $207M as of September 30, 2024, expected to fund operations into 2026.

• No approved products or revenue; operations funded by equity, debt, and warrant exercises.

• Commercial preparations for COMP360 continue, focusing on billing codes, DEA rescheduling, KOL engagement, and payer readiness.

Financial highlights

• Q3 2024 net loss was $38.5M ($0.56 per share), up from $33.4M ($0.67 per share) in Q3 2023; nine-month net loss was $111.8M ($1.67 per share), up from $85.9M ($1.81 per share) year-over-year.

• Operating expenses rose to $47.9M for Q3 2024, with R&D at $32.9M and G&A at $15.0M.

• Cash and equivalents at September 30, 2024, were $207M; debt under Hercules loan facility was $29.8M.

• Q3 2024 cash used in operations was $22.2M, including a $13.6M R&D tax credit; excluding the credit, operational cash use was $35.8M.

• PIPE warrant exercises provided $37.3M in proceeds YTD; up to $122.4M more possible if fully exercised.

Outlook and guidance

• Cash runway expected to fund operations at least into 2026, with ongoing analysis to potentially extend further.

• Q4 2024 net cash used in operations expected between $37M-$43M; full-year 2024 guidance is $114M-$120M.

• Focused on completing phase III COMP360 trials and preparing for regulatory submission; both COMP005 and COMP006 data required for NDA filing.

• Additional capital may be raised via equity, debt, or partnerships; PIPE warrant exercises not guaranteed.

• Commercial launch preparations include state rescheduling, patient flow optimization, and payer engagement.